Profusa Finalizes Prospectus for Resale of 179.3M Shares, Enabling Massive Dilution Amidst Delisting Threat

summarizeSummary

Profusa filed a prospectus supplement for the resale of 179.3 million shares, enabling a potential dilution of nearly 4000% for existing shareholders, while securing up to $101.67 million in capital for a company facing delisting and a going concern warning.

check_boxKey Events · Financing and Capital Events · PFSA

• Massive Potential Dilution

  The filing registers up to 179,272,293 shares for resale by selling stockholders, which, if fully issued, would increase the total outstanding shares to 180,349,228 from 4,410,268, representing a potential dilution of approximately 3989% for existing shareholders.

• Critical Capital Raise

  Profusa may receive up to $100 million from sales of Purchase Shares to Ascent under its Equity Line of Credit (ELOC) and an additional $1,666,666.50 from the cash exercise of Ascent Inducement Warrants, providing essential funding for its operations.

• Operationalizes Prior Offering

  This 424B3 prospectus supplement finalizes the terms and enables the actual sale of shares previously registered under the S-1 filing (Registration No. 333-295364) on April 28, 2026, making the significant dilution imminent.

• Company in Financial Distress

  This dilutive financing occurs in the context of Profusa's ongoing financial challenges, including significant net losses, zero revenue, an auditor's going concern warning, and a Nasdaq delisting notice for failing to meet minimum market value requirements.

auto_awesomeAnalysis · PFSA · Industrial Applications And Services

This prospectus supplement finalizes the terms for the resale of up to 179.3 million shares, representing a potential dilution of nearly 4000% for existing shareholders. This action operationalizes the offering previously registered under an S-1 filing on April 28, 2026. While the company may receive up to $100 million from sales under its Equity Line of Credit (ELOC) and an additional $1.67 million from warrant exercises, this capital comes at an extreme cost to current equity holders. This highly dilutive financing is a critical measure for Profusa, which is facing a Nasdaq delisting notice and has received an auditor's going concern warning, highlighting its urgent need for capital to sustain operations despite zero revenue and significant losses.